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Abstract
Coronavirus disease (COVID-19) caused an overwhelming healthcare,
economic, social, and psychological impact on the world during 2020 and first part
of 2021. Certain populations, especially those with Substance Use Disorders (SUD),
were particularly vulnerable to contract the virus and also likely to suffer from a
greater psychosocial and psychological burden. COVID-19 and addiction are two
conditions on the verge of a collision, potentially causing a major public health
threat. There is surge of addictive behaviors (both new and relapse), including use
of alcohol, nicotine, and recreational drugs. This book chapter analyzed the bi-
directional relationship between COVID-19 and SUD by leveraging descriptive
summaries, advanced analytics, and machine learning approaches. The data sources
included healthcare claims dataset as well as state level alcohol consumption to help
in investigating the bi-directional relationship between the two conditions. Results
suggest that alcohol and nicotine use increased during the pandemic and that the
profile of SUD patients included diagnoses and symptoms of COVID-19, depression
and anxiety, as well as hypertensive conditions.
Keywords: COVID-19, pandemic, addiction, smoking, alcohol, opioid addiction,
public health, advanced analytics, linear regression, machine learning model
1. Introduction
The coronavirus disease (COVID-19) has caused a large healthcare, economic, and
psychosocial impact on communities in the United States and around the world in
2020 and first part of 2021. Many communities, especially those with low income and
Substance Use Disorders (SUD), were particularly vulnerable to contract the infec-
tion and likely to suffered from a greater economic and psychosocial burden [1].
Addiction, characterized by a range of mental, physical, and behavioral symp-
toms, claims the lives of millions of people every year around the world [2]. In their
National Survey on Drug Use and Health, Substance Abuse and Mental Health
Services Administration estimated that 22.6 million Americans, 12 years of age or
older (9.2% of the population), have SUD, including alcohol and tobacco use [3].
Furthermore, the long-term treatment has challenges to due frequent relapse [4].
Alcohol consumption and drug addiction cost around 1.5% of the global burden of
disease, and it can be as high as 5% in some countries, according to recent data [2].
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There are two basic settings to treat SUD: inpatient and outpatient. The primary
goal is for patients affected by addiction to be in the most effective, yet least
restrictive environment that allows them to move along a continuum of care,
depending on their personal and medical needs. There are four phases of SUD care:
outpatient treatment, intensive outpatient treatment, residential treatment, and
inpatient hospitalization [5].
Furthermore, SUD treatment programs are often designed based on three basic
models:
• Psychological model that includes behavioral therapy and treats emotional
challenges as the primary cause of SUD.
• Medical model that requires treatment of SUD symptoms by a healthcare
provider. It focuses on the physiological, biological, and genetic causes of the
disease.
• Sociocultural model that aims to modify the physical and social environment of
a person with SUD [5].
Many patients, receiving SUD treatments, may have also problems in other areas
of their life, including but not limited to: physical and mental health issues, rela-
tionship problems, inadequate social and work skills, as well as legal or financial
challenges. As a result, the treatment options should aim to address the entire
spectrum of issues, and not only treat the addiction component [5].
Even with the variety of treatment options for SUD, more than 6,000 people a
month died from overdosing before the pandemic started in the US [6]. In addition
to the continued loss of lives due to addiction, the pandemic also added other
challenges for those suffering from SUD, resulting in additional 2,000 individuals a
month dying from SUD between March and August 2020 [6]. The government
COVID-19 based restrictions, like home confinement, caused enormous economic
burden to communities in the US as well as around the world. Individuals and their
families faced various unwelcome emotional, psychological, and behavioral chal-
lenges, including excessive substance abuse and depression [4], which further
increased the risk for addiction. The COVID-19 related restrictions caused individ-
uals to turn to smoking, alcohol, drugs, including opioids and synthetic drugs like
Fentanyl, as well as gaming activities to deal with the COVID-19 pandemic [6–8].
On the other hand, individuals suffering from addiction were often also part of
low income communities that already faced many significant challenges related to
access to healthcare, quality education, and unemployment. They also were also
more prone to contract infection during the COVID-19 pandemic due to their
underlying comorbid conditions and immune system deficiencies [8, 9].
In this book chapter, the bi-directional correlation between the COVID-19 diagnoses
and SUDwas investigated, and insights were provided to better understand the impact
of the pandemic on addiction occurrence. The research leveragedmultiple analytics
methods from descriptive statistics, through a simple linear regression, and selected
machine learningmodels to analyze this relationship. The data sources utilized for the
analysis included healthcare claims dataset and the state level alcohol consumption.
2. Literature review
The COVID-19 pandemic caused limited social interactions for individuals
around the world due to the strict national, state, and local governmental
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restrictions [10, 11]. As a result of the restrictions, many individuals started using
tobacco, alcohol, and other substances to help with stress related symptoms. On the
other hand, the increased restrictions and home confinement reduced the substance
exposure, but also resulted in more pronounced cravings and withdrawal effects in
current users. Selected articles have cited a substantially increased number of drug –
and alcohol – withdrawal cases and hospitalizations, which were potentially putting
burden on the already strained health care systems [12, 13].
Opioid addiction and its management was often discussed SUD type in the
COVID-19 era. Opioid addicts particularly faced a challenge due to difficulty in
accessing healthcare services, imposed restrictions on prescription and over-the-
counter drugs, closures of rehabilitation centers, and an increased risk of life-
threatening withdrawals [14]. While loosening of restrictions were recommended
for home-based self-injections and long-acting formulations of methadone and
buprenorphine to mitigate these problems, there was also fear of overdosing and
fatalities [15, 16].
Due to the financial burden and an uncertain future as a result of the pandemic,
gambling activities also increased to unprecedented levels [17, 18]. Eating disorders
and compulsive buying were progressively being reported [19, 20]. COVID-19
pandemic created a vicious cycle of stress, depression, social isolation, anxiety,
excess leisure time that led to surge of behavioral addictions, resulting in mood
alterations, irritability, anxiety, and stress [19, 20].
3. Data and methodology overview
There were multiple types of data utilized for this research. The first source of
the data is represented by the healthcare claims database with the study time period
from January 31, 2019 to December 31, 2020. Patient cohorts: study target and
control were established, using SUD and COVID-19 ICD 10 diagnosis codes. The
diagnoses codes are listed in the appendix. The healthcare claims dataset included
diagnosis codes, medical and surgical codes, therapeutics and treatments
prescribed at the transactional level. In addition, socioeconomic variables, including
age, gender, race, education and incomes levels were leveraged to provide addi-
tional insights into the characteristics of patients with SUD during COVID-19
pandemic [21].
The second dataset employed for the study represented the State Level Alcohol
Consumption trends for 2019 and 2020. The 2020 data was available, however, only
through end of September. For this analysis, alcohol consumption data on per
capita, alcohol sales from 19 states (Alaska, Arkansas, Colorado, Connecticut,
Delaware, Florida, Illinois, Kansas, Kentucky, Louisiana, Massachusetts, Missouri,
North Dakota, Oregon, Tennessee, Texas, Utah, Virginia, and Wisconsin) by type
of alcoholic beverage was leveraged. Only information from the states noted above
was used due to limited availability of data from other states [22].
A number of analytical methods was employed for the analysis from the rules-
based patient qualification criteria, descriptive statistics, linear regression analysis
to machine learning algorithms in order to understand the bi-directional relation-
ship between SUD trends and the COVID-19 surge.
3.1 Healthcare claims patient level database
The healthcare claims database is an anonymous longitudinal patient data set
that can help researchers, healthcare providers, and pharmaceutical companies in
the design of research studies in order to aid comparisons of diagnosis and
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treatment outcomes that represent individual patient-based experiences and inter-
actions with the US healthcare system [21].
The healthcare claims database leveraged for this study consisted of medical,
hospital, and prescription claims across all insurance payment types. As shown in
Figure 1, the database covers more than 317 million patients in the US, spans over
more than 17 years of medical health history, and includes more than 1.9 million
healthcare providers [21]. The data elements used for the study included diagnoses
codes for SUD and other comorbid conditions, procedures and treatments, payment
types: commercial, Medicaid, Medicare and cash, along with patient
sociodemographic characteristics like age, gender, race, education and income
levels, as well as geography [21].
3.2 Methodology overview: Linear regression introduction
One of the methods utilized to analyze the relationship between addiction and
the COVID-19 pandemic was a linear regression approach. In statistics, linear
regression is a linear method to modeling the relationship between a scalar response
(dependent variable – y) and one or more explanatory variables (independent
variables – x):
y ¼ f xð Þ (1)
When there is only one explanatory variable, the regression is called a simple
linear regression. When there are more than one independent variables, the process
is called a multiple linear regression [23].
In a linear regression, the relationships are modeled using linear predictor func-
tions, whose model parameters are estimated from the data [24]. Linear regression
focuses on the conditional probability distribution of the response given the values
of the predictors, which is the domain of multivariate analysis [24].
There are several metrics often leveraged to evaluate the model performance: R-
squared and F-statistic. R-squared also called the coefficient of determination is the
proportion of the variance in the dependent variable that can be explained by the
variation in the independent variable(s). The value of the metric ranges between 0
and 1, and the higher value represents a better performance of the model [24]. An
F-test represents a statistical test often used when comparing statistical models
employed on the studied datasets to identify the model that best fits the population
from which the data sample was drawn [24].
Figure 1.
Healthcare claims patient level database description.
4
Addictions - Diagnosis and Treatment
3.3 Machine learning introduction
Machine learning is a subfield of the artificial intelligence area, which includes
statistics, mathematics, computer algorithms, etc. focused on building applications
that learn and improve their predictive capabilities automatically over time without
being specifically programmed to do so. Machine learning models are built upon a
statistical framework, since they involve data elements often described, using sta-
tistical distributions and assumptions. These algorithms gained in popularity in the
recent years due the increased amounts of data availability and significant
advancements in the computing power [25].
In this book chapter, selected algorithms were leveraged to analyze the relation-
ship between SUD and COVID-19 diagnoses. The analysis identified factors beyond
the pandemic, such as patient characteristics: age, race, education and income
levels, comorbid conditions (example: diabetes, hypertension, mental health), con-
comitant treatments that increased the addiction diagnoses, including patients most
likely to struggle with SUD, regions of greater prevalence, and comorbid conditions
presented along with SUD and COVID-19 diagnoses.
3.3.1 Supervised learning algorithms
Supervised learning is the process of training or building machine learning
algorithms, in which algorithms learn to map from input space (X) to output space
(Y) [26].
Y ¼ f Xð Þ (2)
The major objective is to approximate the mapping function (f) in order to
predict (y) outcome when a new data point (x) is added [26]. Supervised learning
algorithms are mainly used for classification and prediction problems [27]. The
following are examples of supervised algorithms: logistic regression, decision trees
(DTs), random forest (RF), extreme gradient boosting (XGBoost), support vector
machines (SVMs), naïve bayes, adaptive boosting (AdaBoost), and artificial neural
network (ANN) [28].
3.3.2 Unsupervised learning algorithms
Unsupervised learning algorithms, on the other hand, learn the hidden patterns
within the input dataset (X) [29]. These models are called unsupervised, because
there is no supervision to guide them, and the algorithms learn, discover, and
display the patterns in the input data (X) [30]. These algorithms are often employed
to uncover the natural clusters, dimension reduction, anomaly detection, etc.
Examples of unsupervised algorithms include: k-means clustering, principal com-
ponent analysis (PCA), factor analysis (FA), singular value decomposition (SVD),
apriori algorithm (association rule) [28].
Depending on the study objectives and the available data type, algorithms are
tested for performance, data type fit, and are selected accordingly. A random forest
and an extreme gradient boosting models were selected to explain the bi-directional
relationships of the SUD trends and COVID-19 pandemic surge.
3.3.3 xExtreme gradient boosting
Gradient boosting algorithm is an ensemble of weak prediction models, mostly
decision trees [31]. XGBoost starts by creating a first simple tree [32, 33], which
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than adds other trees, and builds upon the weaker learners. The model learns with
each iteration and revises the previous tree until an optimal point is reached [34].
Feature importance is the value mostly generated by tree-based models like
decision trees, random forest, XGBoost, etc. [31] and signifies the importance of
features in the model in predicting the outcome. It represents how good the feature
is at reducing node impurity. It is widely known as ‘gini importance’ or ‘mean
decrease impurity,’ and is defined as the total decrease in node impurity averaged
over all trees of the ensemble [32]. Importance is mostly calculated as: weight, gain
and cover, where ‘weight’ is the number of times a feature is present in a tree, ‘gain’
is the average gain of splits, while ‘cover’ is the average coverage of splits, with
‘coverage’ being defined as the number of samples affected by the split [33].
3.3.4 Random forest
Random forest or random decision forest is an ensemble learning method for
classification and regression analysis that constructs an array of decision trees during
the training timeframe. The output of the random forest for the classification task is
the class selected by the majority of trees, while for the regression task, the output
represents the mean or average prediction across individual trees [35, 36].
3.3.5 Chi-square test and p-value
The Chi-square test is one of the most widely used non-parametric tests [37],
often utilized to test the independence between observed and expected frequencies
of one or more attributes in a contingency table, known as ‘goodness of fit test’ [38].
The p-value, also used in this study, evaluates the statistical significance of the
predictor variables. The significance level was set at the 5% and 10% to aid the
feature importance evaluation and statistical results’ interpretation [24, 38].
3.3.6 Classification metrics
The following classification metrics were leveraged to validate the machine
learning models’ performance. A confusion matrix is often generated from the
predicted probability values with 0.5 as the classification threshold. Patients with
probability value greater than or equal to 0.5 are noted as 1 and below 0.5 are noted
as 0 [38].
Confusion matrix:
• True Positive (TP) – Target patient correctly identified by the model as target
patient
• False Positive (FP) – Control patient misclassified by the model as target
patient
• True Negative (TN) – Control patient correctly classified by the model as
control patient
• False Negative (FN) – Target patient misclassified by the model as control
patient
Model performance metrics:
• Accuracy: % of total patients correctly identified among total patients
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• Positive Predictive Value (PPV, Precision): % of true target patients among
total predicted target patients
• True Positive Rate (TPR, Sensitivity, Recall, Hit Rate): % of true target patients
who were correctly identified among total target patients
• False Positive Rate (FPR): % of true control patients incorrectly identified
among total control patients
• Specificity: % of those control who will have a negative target result
• F1 Score: is the harmonic mean of precision and recall
• AUC: Area Under the Receiver Operating Characteristic (ROC) Curve. To
validate the trade-off between true positive rate and false positive rate [38].
4. Analysis results and discussion
4.1 Substance usage disease trends overview
This section provides an overview of SUD trends for 2019 and 2020 when
leveraging the healthcare claims dataset that was discussed in the earlier section of
the chapter. The summary includes information on the overall trends, patient
demographics, and insights into the COVID-19 diagnosis rates. The first part of the
analysis was to review and understand the SUD diagnoses trends as well as COVID-
19 infection rates within the SUD population. The focus of the analysis was on the
SUD population only to understand changes in trends during the pandemic.
The monthly trends of patients with SUD diagnoses presented that the addiction
trends stayed consistent over 2019 and 2020, with the exception of April–May 2020
timeframe. The list of SUD diagnoses is presented in the appendix refers to
Tables 6–9. At the beginning of the pandemic (April–May 2020), there was a
decrease in the number of patients with addiction diagnoses. A two sample t-test
that compared the SUD diagnosis counts between April–May 2019 and April–May
2020 revealed that the difference in counts was not significant at either the 5% or
10% significance level. However, the directional decline might have been a result of
the state enacted restrictions, including home confinement as well as the inability to
hold in-person HCP office visits and elective procedures (Figure 2).
The SUD diagnoses trend data also involved analyzing trends by splitting the
patient cohort into newly diagnosed patients in the last 12 months as well as previ-
ously diagnosed patients within the same timeframe. The analysis presented that
the share of newly diagnosed patients vs. previously diagnosed declined slightly
between 2019 and 2020, but the difference was not statistically significant. In 2020,
newly diagnosed patients accounted for 62% of all patients vs. 66% in 2019. In
addition, patients diagnosed with addiction as well as COVID-19 represented 3% of
the newly diagnosed patients and 4% of those with already a diagnosis.
Furthermore, several different types of SUD experienced a decline in the num-
ber of patients diagnosed at the start of the pandemic. Opioid dependence was the
leading addiction type with alcohol dependence following as next most frequently
diagnosed SUD (Figure 3). The counts of opioid dependence diagnosis were statis-
tically different from the counts for other types of SUD. Statistically significant
difference in trends at 5% significance level was also observed between opioid
dependence and alcohol dependence, opioid dependence vs. cannabis dependence,
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sedatives dependance vs. cannabis dependance, and sedatives dependence vs.
alcohol use. The addiction diagnosis codes are noted in the appendix. Patients with
psychoactive type of addiction represented a higher share within the COVID-19
diagnosed population (19%) as compared to the overall share (3%). Psychoactive
SUD is referred to as addiction type with hallucinatory symptoms. The COVID-19
patient distribution for other addictions was very similar to the overall addiction
population.
An additional analysis of demographic and geographic attributes as presented in
Table 1 revealed that males presented a higher percentage of the SUD population
compared to SUD and COVID-19 population, but the percentage was not statisti-
cally significantly different from the percentage of women SUD patients. On the
other hand, patients using cannabis appeared younger compared to the rest of the
SUD population. This finding was statistically significant based on a two sample t-
test (p-value = 0.00, statistically significant at 5%).
Most of both SUD and COVID-19 patients had commercially provided insurance
coverage (70%), while 30% of patients had a government provided healthcare
insurance (p-value = 0.00, statistically significant at 5%). Inhalants and rehabilita-
tion drug addiction represented the highest share of patients with commercial
insurance with more than 75%.
Figure 3.
Addiction monthly patient count trends, 2019–2020.
Figure 2.
Addiction monthly patient count trends, 2019–2020.
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Furthermore, the North East and Midwest regions represented two main geo-
graphic areas of the United States with the highest level of patients diagnosed with
SUD and covered more than 50% of the total addiction diagnosed patients. The
share of patients in these two regions was statistically significantly higher compared
to the rest of the US regions (p-value = 0.00, statistically significant at 5%). The
West regions on the other hand covered approximately 20% of the addiction diag-
nosed population.
The SUD treatment pattern analysis revealed that the procedural services,
including psychotherapy, recommended to treat SUD patients declined in April and
May 2020 and then returned to similar levels before the pandemic and on par with
Table 1.
Patient demographic summary (age and gender).
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the 2019 trends (Figure 4). The decline was statistically significant at the 10%
significance level with a p-value = 0.07. The decline might have been related to the
imposed country-wide lockdown during the two months on 2020.
On the other hand, the number of patients treated with prescription medications
statistically significantly increased between 2019 and 2020 (p-value = 0.00, statisti-
cally significant at 5%), even during the pandemic, the trend continued to increase,
implying that patients continuously were receiving patient care (Figure 5). The drugs
names are presented in the appendix. Prescription treatments for drug related addic-
tion had the highest share of the treatments, followed by addiction relapse treat-
ments. The share of drug prescription treatments was statistically different from the
other types of therapy, including relapse and alcohol treatments.
4.2 Alcohol consumption overview
This section of the book chapter provides an overview of alcohol consumption
trends for 2019 and 2020. For this analysis, alcohol consumption data on per capita,
alcohol sales from 19 states (Alaska, Arkansas, Colorado, Connecticut, Delaware,
Florida, Illinois, Kansas, Kentucky, Louisiana, Massachusetts, Missouri, North
Figure 4.
Procedural treatment trends, 2019–2020.
Figure 5.
Addiction Rx treatment monthly patient count trends, 2019–2020, by addiction type.
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Dakota, Oregon, Tennessee, Texas, Utah, Virginia, and Wisconsin) by type of
alcoholic beverage was leveraged. The limited alcohol consumption information by
state was due to the limited data availability at source [22].
The monthly trends of pure alcohol (gallons of ethanol) from 2019 and 2020 in
Figure 6 showed that the trend stayed nearly the same, with a only a directional
increase in 2020 [22]. A two sample t-test did not present statistically significant
differences between the yearly trends. On the other hand, it was observed that with
the increase in COVID-19 cases in the middle of pandemic (June–August 2020), there
was an associated increase in the consumption of pure alcohol, as evident from the
high Pearson correlation coefficient of 0.87 between the alcohol consumption and
COVID-19 diagnosed number of patients. The increase in the alcohol use might have
been associated with individuals experiencing hardship due to the prolonged lock-
downs, loss of job, and the overall changes in lifestyle as a result of pandemic, and
alcohol being perceived as a way for coping with the changing environment.
The trends describing gallons of alcohol per capita for age 14 and older
(Figure 7) showed a statistically significance increase (p-value = 0.04, statistically
significant at 5%) in gallons per capita from mid-May 2020, which might be a result
of the COVID-19 pandemic spread. This was also apparent from a strong a Pearson
correlation coefficient of 0.91 between the pandemic outbreak as denoted by a
volume of patients diagnosed with COVID-19 and gallons of alcohol per capita [22].
In order to understand the alcohol consumption over time, the percentage
change in gallons of alcohol per capita from 2017 to 2019 (a 3-year average) to 2020
Figure 6.
Monthly avg. of pure alcohol (gallons of ethanol) across United States.
Figure 7.
Gallons of ethanol per capita age 14 and older (2019 and 2020).
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was analyzed (Figure 8). Overall, a visible increase in the trend was noticed;
however, in May 2020, a statistically significant decline in the percentage in alcohol
consumption (p-value = 0.06, statistically significant at 10%) was observed due to
the COVID-19 imposed lockdowns and closures of liquor stores. From the month of
June onwards, a statistically significant increase in the percentage change (p-value =
0.06, statistically significant at 10%) was noted, which might have been associated
with the lockdown restrictions being partially lifted, leading to re-opening of liquor
stores and increased purchasing levels [22].
Figure 9 depicts a comparison of selected states’ gallons of alcohol consumption
per capita between 2019 and 2020. As noted earlier, only a few selected states were
considered for the analysis due to the limited availability of the data at the source. For
most of the states, an increase in alcohol (in gallons) per capita is noticeable in 2020.
Delaware’s excise tax on liquor of $3.75 per gallon, lower than 72% of the other 50
states, led to the highest increase in per capita alcohol in 2020. Most of the states
experienced an increase in per capita alcohol during the COVID-19 pandemic [22].
The alcohol consumption data was also analyzed for each alcohol type. Figure 10
presents a yearly consumption comparison between 2019 and 2020 for beer, wine
and spirits. It was observed that beer consumption was higher in January and Febru-
ary in 2020 compared to January and February in 2019, but after the COVID-19
pandemic started, the consumption decreased from March onwards until May 2020
Figure 8.
Percentage change in gallons of ethanol per capita age 14 and older from 2017 to 2019 (3-year average) to
2020. Note: Limited states shown due to unavailability of the data from the source.
Figure 9.
State wise three-year average gallons of ethanol per capita age 14 and older, 2017–2019 and 2020.
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due to lockdowns and limited liquor facilities opened in each state. For wine and
spirits, the trend of consumption showed an increase, starting from January 2020
onwards [21]. It was also evident that the increase in volume of beer, spirit, and wine
consumption from 2019 to 2020 was statistically significant based on the two sample
t-test, which resulted in a p-value < 0.02 for each alcohol type [22].
4.3 Effects of alcohol and substance use during COVID-19
In this section of the book chapter, the effects of alcohol and SUD during the
COVID-19 pandemic were analyzed. An ordinary least square linear regression model
was used to investigate the correlation between these events. The dataset employed
was a combination of the healthcare claims data and the alcohol consumption data,
both aggregated at a state and monthly levels for comparison [21, 22].
The results of the ordinary least square regression are presented in Table 2. The
analysis results showed that sedatives use, alcohol abuse, and beer consumption
were the highly significant variables and positively correlated with the COVID-19
pandemic spread. Sedatives like benzodiazepines are often prescribed for anxiety
and insomnia, confirming the finding [39]. Furthermore, an increased consumption
of alcohol might have led to seeking treatments to manage the signs of frustration,
sadness, mental health conditions, and stress [40], caused by the prolonged
isolation during the pandemic.
Other parameters like opioid use, cannabis use/abuse were significant as well,
but they were negatively correlated with the pandemic spread. These results were
consistent with previous research articles, presenting that drug use declined during
the pandemic while at the same time patients suffered from withdraws and other
symptoms related to fewer substances available for consumption [12–14, 41, 42].
On the other hand, while beer consumption was positively correlated with COVID-
19 pandemic trends, the consumption of spirits presented the reversed correlation,
which was contrary to the findings of overall alcohol trend increases. The difference
in correlation might have been related to the differences in states regulations of the
different types of alcohol, which in turn might impact the alcohol type availability
for consumption at the state level [43].
The model significance was evident from the F-statistic value of 14.7 with an
adjusted R square value of 74%, which informed that a relatively high proportion
of the variations in the data could be explained by the predictor variables.
Figure 10.
Average beverage consumption breakout by wine, beer and spirit from 2019 and 2020. Note: 2020 data is
available only until Sep due to limited availability from the source.
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4.4 Machine learning: important features leading to addiction
To understand the parameters associated with SUD and identify if the COVID-19
pandemic impacted the addiction diagnosis rate, supervised classification machine
learning algorithms, including random forest and XGBoost were performed.
4.4.1 Dataset overview
As a part of the analysis, two distinct patient cohorts: study target and control
groups were developed to allow for analysis of the SUD and COVID-19 trends. The
distinction between these two groups permitted the machine learning models to learn
Note: Per capita alcohol sales from 19 states (Alaska, Arkansas, Colorado, Connecticut, Delaware, Florida, Illinois,
Kansas, Kentucky, Louisiana, Massachusetts, Missouri, North Dakota, Oregon,Tennessee,Texas, Utah, Virginia, and
Wisconsin) by type of alcoholic beverage.
Table 2.
Ordinary least square regression analysis results.
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the variations in the data and identify the important variables that best distinguished
between both groups. The target group was defined by the patients in the data from
October 2020 to December 2020, who had at least 2 addiction diagnoses, followed by
a treatment after initial diagnosis, and the control group was defined by the patients
from October 2019 to December 2019, having two addiction diagnoses, followed by a
treatment after initial diagnosis. A sample of 20,000 records were randomly
selected for the modeling exercise based on similar age and gender distribution as in
the target group. Two months of historical claims data related to diagnosis, proce-
dures, and pharmacological treatment were pulled from initial diagnosis event along
with other demographic data elements like age, gender, income, education, etc. The
healthcare claims level data was converted to patient level records, using data pre-
processing steps, and a final data structure with  20,000 records and 15,000
features was created for machine learning modeling [21].
4.4.2 Feature selection
The data elements used for the study included diagnosis, procedures, and phar-
macological treatments along with other demographic features like age, gender,
income, education, etc. Since the number of features was15,000, the data element
dimension needed to be reduced to a more manageable number.
In order to reduce the variables’ space and select the top features, the LightGBM
and Boruta algorithms were leveraged for the purposes of dimension reduction.
LightGBM is a gradient boosting framework, which uses tree-based learning,
whereas Boruta is a feature selection algorithm, a wrapper built around RF Classifi-
cation algorithm. The top features from both the algorithms were selected for the
machine learning algorithms development [44].
Table 3 below represents a list of selected features important in the preliminary
run of the models. Data elements related to the COVID-19 diagnoses and associated
symptoms along with alcohol and nicotine use as well as major depressive disorder
were noted as important variables, separating the 2020 and 2019 SUD patient cohorts.
4.4.3 Machine learning models overview
In order to understand the underlying factors for the SUD 2020 and 2019 patient
cohorts and investigate if there was an association with the COVID-19 pandemic,
the following machine learning models were applied: random forest and XGBoost.
Hyper tunning process was also performed to optimize the models. Below a brief
methodology overview is presented.
Random forest is a classification algorithm, consisting of many decision trees
that use bootstrap aggregation, bagging and feature randomness when building
each individual tree. It creates an uncorrelated forest of trees whose prediction is
more accurate than that of any individual tree. The model outcome provides esti-
mates of variables important in the classification [45].
XGBoost is a decision-tree-based ensemble machine learning algorithm that uses
a gradient boosting framework. XGBoost approaches the process of sequential tree
building, using parallelized implementation. Each model run learns from the error
of previous models and weak learners. It incorporates the error of weak learners in
the ensemble model and re-runs the process. It uses bootstrap aggregating tech-
nique, also called as bagging, which implies diving the data into sub samples for
each iteration of model training. For prediction purposes, the model chooses
majority of the vote from all the learners [46].
Hyper parameter tuning is the optimization process of finding the model
parameters to improve the model performance. The objective is to minimize the
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cost function, hence reduce the error caused by the model. It uses gradient descent
algorithm, which initially randomly assigns the model parameter to calculate the
cost function and later improves it at each step, so that the cost function assumes a
minimum value. Mathematically, it takes the derivative of the sum of squared
residuals and equates it to 0 to find a point where the function is changing [47].
4.4.4 Machine learning analysis details
The machine learning algorithms were evaluated for the different performance
metrics as noted in the earlier section of the book chapter. Initially, the models were
overfitting, as they seemed to capture most of the variations from the training data,
as well as at the same time captured the noise from the data. This resulted in many
negative records misclassified as positive, which might have led to a considerably
lower precision value.
As noted in Table 4, the baseline models, random forest resulted in AUC of 73%
and XGBoost resulted in AUC of 74% with recall of 74.08% and 82.80% respec-
tively. While working with healthcare claims data, a higher ratio of false negative
records is perceived as a large problem. For example, predicting a sick patient as
Table 3.
Preliminary important data features.
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healthy, because ideally the patient should have received the treatment on time,
may lead to health complications and even potentially death. Thus, it is advised to
minimize the number of false negative observations, which will result in a higher
recall, depicting an inverse relationship between the two, also called true positive
rate or sensitivity. However, the initial baseline models resulted in a comparatively
lower recall. To improve the model accuracy, the hyper parameter tuning was
executed to find the best model parameters.
In addition, F1 score was defined as follows:
2 ∗ Precision ∗Recallð Þ= Precisionþ Recallð Þ (3)
which is a function of precision and recall and should be maximized such that
both precision and recall both are optimal [45–47]. Hyper parameter tuned models
not only improved the recall, but also slightly improved the F1 scores for random
forest and XGBoost to 69.4% and 69.57% respectively, implying a robust model
sensitive to false negative observations.
The machine learning models were retrained, using a few model parameters,
including mex=depth, min-samples_split and max_features. In order to obtain the
optimal values of model parameters, k fold cross validation with 5 iterations were
used in the hyper parameter tuning process [47].
Using the optimal values of the model parameters obtained from hyper param-
eter tuning, the models showed an improvement in the model performance, which
was evident from the model metrics. As shown in Table 4, the recall significantly
increased for both of the models and also, the F1 scores slightly improved compared
to the baseline models. This resulted in a decrease in the false negatives count,
which led to an increase in recall.
Figure 11 depicts the final ROC AUC plot, which shows the relationship between
the true positive rate and the false positive rate at different probability thresholds. A
true positive rate also known as the sensitivity metric, which informs the propor-
tion of positive records that were correctly classified over the total number of
positive records. A false positive rate is the proportion of negative records
misclassified over total number of negative records [38]. Both random forest and
XGBoost resulted in AUC of 75% with recall of 94.7% and 85.6% respectively, which
improved from the baseline models.
4.4.5 Machine learning model interpretation
The random forest and XGBoost models identify features, which were a combi-
nation of SUD as well as COVID-19 data elements. Table 5 presents the top
Table 4.
Machine learning model metrics.
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important features. The importance of the features was measured using the ‘gini’
importance metric, which calculated the impurity in the node. The metric measured
how each feature decreased the impurity of the split, while making the decision tree
in the algorithm and averaging it over all the trees in the forest, resulting in the
measure of feature importance [32, 33].
Features like nicotine dependence, alcohol abuse, long term drug therapy, disul-
firam [48], methadone [49] were presented as important in explaining the differ-
ences in SUD patient cohorts between 2019 and 2020. For example, the value 0.003
of nicotine dependence importance denoted that the impurity reduced in the node
by adding the variable, which thus contributed to the model robustness and a higher
accuracy level. The effects of pandemic on individual’s lives were not only restricted
to patients’ physical health, but also affected their mental health, as noted by the
major depressive, anxiety diagnoses, and suicidal tendencies as presented in the top
most important healthcare data elements. The unexpected and unwanted change
enforced on daily lives, drastically increased the stress levels. Difficulties in man-
agement of the changing environment and following preventive measures, such as
undergoing lockdowns, fueled the stress levels even more. The economic downturn,
leading to unemployment, and low consumer confidence played an imperative role
in increasing the stress levels as well. As a result of the prolonged stress and anxiety
due to the lockdowns, the consumption of alcohol, smoking, and other nicotine-
based products increased [12, 13, 41, 42].
Figure 11.
ROC AUC curve of random forest and XGBoost.
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Table 5.
Top most important healthcare related features.
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It was also interesting to see features related to COVID-19 pandemic being noted
as important differentiators between the 2019 and 2020 SUD patient cohorts. The
features included COVID-19 diagnosis and related symptoms: headache, cough,
acute upper respiratory infection, specimen collection for severe acute respiratory
condition. Procedures noting HCP in-office and tele-visits along with in-patient
hospital or ER visits were also noted as important variables, further highlighting
that the amount of care might have increased as a result of SUD, but also due to
COVID-19 diagnoses and related symptoms. In addition, medications often used to
treat viruses and infections like Azithromycin were also presented as important data
elements defining the 2020 SUD patient cohort.
Furthermore, the cohorts differed on the occurrence of the comorbid conditions,
such as chronic kidney condition, hypertension, hyper lipidemia, and gastro-
esophagus conditions, which might inform a potential impact of a larger alcohol and
other substance abuse activities during the pandemic or simply present that the
patient profile changed during the pandemic, expanding the definition of the SUD
patients group. There were also several data elements identifying SUD treatments
such as Narcan, methadone to list a few and procedures related to drug testing,
blood panels, and other related treatments, which present an increased rate of
addiction testing and treatment between the two periods, confirming earlier find-
ings of increased SUD treatment trends. The analysis also presented differences of
the cohorts on a diagnoses for lower back pain and pain relieve medications use.
From the sociodemographic data elements, patients diagnosed with addiction or
treated for addiction presented characteristics that can help further define the patient
profiles for individuals that were likely for developing SUD during the pandemic. For
example, the average age of 42 was observed for the impacted population. Ethnicity
of Caucasian and Black/African American was also noted as prevalent. Patients with
nicotine dependence, alcohol dependence, opioid use, and cannabis dependence were
relatively more prevalent in the states of Florida and Texas. These states presented a
relatively higher volume of patients with specific SUD diagnoses compared to other
states. The impacted patients presented some college or achieved at least a high school
diploma as well as were more likely to be associated with the lower economic status
communities, with income level being less than $30 K annually. The educational and
economic levels were noted by other published articles, presenting the economic
impact and increased risk for COVID-19 virus within low income population [2].
5. Conclusions and study limitations
This book chapter investigated SUD and the resulting impact from the COVID-
19 pandemic on the rate of diagnoses and treatment. Overall, the diagnoses rate of
SUD was consistent over time in 2020 compared to 2019 (except for April and
May); however, a statistically significant increase in treatment of different addic-
tion types was noted during the pandemic. In 2020, newly diagnosed patients
accounted for 62% of all SUD patients compared to 66% in 2019, but the difference
was not statistically significant. Furthermore, the changes in procedures performed
for addiction testing significantly declined at the beginning of the pandemic and
then returned to normal levels in June of 2020, while the SUD treatment signifi-
cantly increased between 2019 and 2020. In addition, patients diagnosed with
addiction as well as COVID-19 represented 3% of the newly diagnosed patients and
4% of those with already a diagnosis. Patients using cannabis were found statisti-
cally significantly younger compared to the rest of the SUD population.
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In 2020, a noticeable increase in alcohol consumption and drinking behaviors
was observed compared to 2019, including an increase in the average gallons con-
sumed by alcohol type: spirits, wine, and beer. Compared to the previous years, a
statistically significant positive percentage change in gallons of alcohol per capita
from 2017 to 2019 (a 3-year average) to 2020 was observed [22], which could be
related to the increased stress levels due to the pandemic spread and prolonged
lockdowns [50].
Machine learning analysis of SUD patient cohorts between 2020 and 2019
presented that the patients in the 2020 cohort who were diagnosed with SUD, were
also often diagnosed with either COVID-19 or related symptoms, including head-
ache, upper respiratory infection, and cough. Furthermore, it is likely that SUD
patients with addiction to drugs and nicotine products were more likely to contract
COVID-19, as a result of their weaker immune system due to lower white cells
levels in the blood [51, 52]. The analysis also presented the importance of HCP
in-office and tele-visits along with in-patient hospital visits that could be related to
the increased level of SUD treatment, but also present the severity of COVID-19
related symptoms and the need for treatment.
Moreover, excess alcohol consumption identified as one of the important fac-
tors, differentiating between the two SUD patient cohorts could lead to immune
deficiency, causing increased susceptibility to certain diseases. Prolonged alcohol
abuse may cause disruptions to the digestive system and could result in liver failure.
Alcohol use may also affect individual’s ability to store adequate amounts of protein
and nutrients. Most importantly drugs and alcohol affect white blood cells, which
act as the defense system for the body. The weaker defense system can increase the
risk of developing life-ending diseases [52].
Finally, based on the machine learning analysis, the SUD patient cohorts dif-
fered on occurrence of the comorbid conditions such as chronic kidney condition,
hypertension, hyper lipidemia, and gastro-esophagus condition, which might pre-
sent that the SUD patient profile changed during the pandemic due to the changes
in the life style and increased consumption of alcohol and tobacco. Additional
investigation should be conducted to further examine the patients’ health history
and understand the underlying reasons for the differences in the SUD patient
cohort characteristics.
5.1 Study limitations
Due to the timing of writing this book chapter, not all data was available for the
entire year of 2020 to allow for a comprehensive analysis. Adding the additional
data for alcohol consumption, as well as data for recreational drug use by state
during the pandemic could enhance the analysis in presenting the SUD population
characteristics including their health, mental, and economic state. Furthermore, it
might also be helpful to add COVID-19 vaccination data by state in order to under-
stand the effects of vaccinations and COVID-19 variants on general virus trends as
well as SUD impacted populations.
Additionally, the healthcare patient level claims data, comprising of prescrip-
tion, medical, and hospital claims can also observe gaps in the coverage of long-term
care institutions, mental health hospitals, correctional facilities, and other institu-
tions with a limited public reporting, and result in a potential bias in the studied
population when compared to the entire US population. Furthermore, the COVID-
19 related symptoms’ diagnoses might also skew the analysis and overestimate the
impact of COVID-19 on the SUD population. The statistical results could be
23
Leveraging Advanced Analytics to Understand the Impact of the COVID-19 Pandemic on Trends…
DOI: http://dx.doi.org/10.5772/intechopen.99639
further enhanced and become more robust with the additional data availability and
understanding of the diagnosis codes for the COVID-19 related symptoms.
Since the COVID-19 pandemic was a rare event, it became a new topic of
interest for analysis. As a result, there was a limited number prior research studies
conducted on this topic, which posed a challenge in creating a theoretical founda-
tion for this book chapter’s research questions and hypothesis. With little prior
research, developing an entire new research typology was challenging.
The scope of the analysis can also be enhanced via adding additional data sources
and having a longer timeframe to evaluate the impact of pandemic on addiction and
health impact of those impacted by either condition. Furthermore, new set of
advanced analytics, including deep learning and natural language processing (NLP)
approaches, could be applied to create data driven evidence to confirm newly
established hypothesis, research objectives, and results.
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Table 6.
Substance abuse disorder diagnosis codes.
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Table 7.
Substance abuse disorder procedure codes.
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Table 8.
Substance abuse disorder treatment codes.
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